Purpose: To describe the in
vitro efficacy of novel ocular anti-infective / anti-inflammatory agent
CLSA_1506 against several common ocular pathogens including bacteria and
fungi. Methods: One volume of a 2.2% (w/w) solution of CLSA_1506 was
added in trypticase soy broth mixtures with ocular
isolates of Pseudomonas aeuroginosa, Proteus
Staphylococcus epidermidis, Streptococcus pneumoniae, Methicilin
Resistant Staphylococcus Aureus and Klebsiellapneumoniaeand
in malt extract broth mixtures with ocular isolates of Candida parapsilosis, Candida albicans
and Apergillusniger. After
the treatment of pathogens with the analyte (drug),
a 100 microliterinnoculum
was immediately removed and plated onto standard culture media at indicated
inoculation times of 0 (immediately after the treatment), 24 and 72 hours.
Plates were monitored for microbial growth and colony counts obtained at 24
hours for bacteria and 3 days for yeasts and 5 days for fungi.
For HdaV-4 assay, a 0.5 mL aliquot of 2.2% (w/w)
solution of CLSA_1506 was combined with 0.5 mL of
virus stock in a sterile tube. The tubes were then incubated at 37°C for 30
minutes. Hank’s Balanced Salt Solution (HBSS) was used as the negative
control. Infectivity of A549 cells was determined. Immediately following
incubation the test and control articles were titrated for infectious HAdV-4. Results: For all species tested, no growth of any
microbial colonies was noted for any species after incubation periods for 0,
24 or 72 hours. A control group (with no analyte
treatment) was observed for growth of all species tested. HAdV-4 was
completely inactivated by CLSA-1506. Conclusions: CLSA_1506 eliminates many common ocular pathogens
on contact and may be a useful ocular antibiotic in suspected bacterial,
fungal or mixed infections.
B. Liang, CLS Pharmaceuticals,
Inc., F; K. Lin, Mycometrics, LLC, F.